Skip to content
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Menu
  • Happy Health
  • Happy Mindset
  • Animal Wonders
  • About Us
    • Team
  • Subscribe
Happy News

Every Patient In This Bowel Cancer Trial Has Been Cancer Free For Nearly Three Years

In one of the most striking results from any cancer clinical trial in recent years, every single patient in a bowel cancer study has remained cancer-free for nearly three years after receiving a short course of immunotherapy before surgery, with zero relapses recorded in the entire cohort as of the latest follow-up data. The NEOPRISM-CRC trial, led by researchers at University College London and University College London Hospitals, gave patients with a specific form of stage two or three bowel cancer nine weeks of pre-operative treatment with the immunotherapy drug pembrolizumab, replacing the conventional approach of post-operative chemotherapy. Initial results showed that 59 percent of patients had no detectable cancer after the immunotherapy and surgery combined, and the new follow-up data at 33 months shows that not only have those patients remained clear, but even the patients who still had small amounts of cancer remaining after treatment saw none of it grow or spread. Under the standard treatment pathway, roughly 25 percent of similar patients would be expected to relapse within three years.

The results were presented at the American Association for Cancer Research Annual Meeting in April 2026 and have generated significant excitement among oncologists. The specific bowel cancer treated in the trial, known as mismatch repair-deficient cancer, affects roughly 15 percent of all bowel cancer patients and is characterized by genetic errors that make it particularly responsive to immunotherapy. Researchers noted that the results suggest a nine-week drug course could replace months of chemotherapy and provide more durable protection against recurrence, a potential shift in how this form of the disease is treated from the ground up. Scientists called the zero-relapse figure at nearly three years extraordinary, and said larger trials are now needed to confirm and extend the findings across wider patient populations.

Source: https://scitechdaily.com/breakthrough-bowel-cancer-trial-leaves-patients-cancer-free-for-nearly-3-years/

PrevPreviousColorado Just Banned Pet Store Dog And Cat Sales
NextA 12-Year-Old Fighting Brain Cancer Raised $22 At A Lemonade Stand For Research And Then Something Incredible HappenedNext

Recent Articles

Happy News

Cooking One Home Meal A Week Could Cut Your Dementia Risk By 30 Percent And For New Cooks Its Even More

May 3, 2026

A new study published in the Journal of Epidemiology and Community Health has found that older adults who prepare a home-cooked meal from scratch at least once a week have a significantly lower risk of developing dementia, with the protective effect growing even stronger for people who are just learning

Read More
Happy News

Hotel Staff Worked Through The Night To Donate 2600 Unserved Dinners To Shelters

May 3, 2026

When a gunman fired shots in the lobby of the Washington Hilton on April 25th and abruptly ended the White House Correspondents’ Dinner before the main course could be served, roughly 2,600 plates of steak and lobster were left sitting untouched in the kitchen. The hotel staff, who worked through

Read More
Happy News

This Wouldn’t Have Happened To Leonardo DiCaprio, The Story Of The Lost Oscar

May 2, 2026

It started as a bureaucratic nightmare and ended as one of the most absurd comeback stories of the week. Pavel Talankin, the Russian-born director who won Best Documentary Feature at the 2026 Academy Awards for Mr Nobody Against Putin, was stopped at New York’s JFK Airport on Wednesday when TSA

Read More
« Previous Next »
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
  • Privacy Notice
  • Accessibility Notice
  • Do Not Sell or Share My Personal Information
  • Unsubscribe
  • Terms and Conditions
  • Privacy Policy
Copyright © 2026 HappyNews.